Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix

[1] Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic emphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci. 2017; 18(12): 2532. DOI: 10.3390/ijms18122532 PaolinoG DidonaD MagliuloG IannellaG DidonaB MercuriSR Paraneoplastic emphigus: insight into the autoimmune pathogenesis, clinical features and therapy Int J Mol Sci 2017 18 12 2532 10.3390/ijms18122532 Open DOISearch in Google Scholar

[2] Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004; 9(1): 29–33. DOI: 10.1111/j.1087-0024.2004.00832.x AnhaltGJ Paraneoplastic pemphigus J Investig Dermatol Symp Proc 2004 9 1 29 33 10.1111/j.1087-0024.2004.00832.x Open DOISearch in Google Scholar

[3] Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010; 8(8): 598–606. DOI: 10.1111/j.1610-0387.2010.07380.x ZimmermannJ BahmerF RoseC ZillikensD SchmidtE Clinical and immunopathological spectrum of paraneoplastic pemphigus J Dtsch Dermatol Ges 2010 8 8 598 606 10.1111/j.1610-0387.2010.07380.x Open DOISearch in Google Scholar

[4] Miyashiro D, Sanches JA. Paraneoplastic skin disorders: a review. G Ital Dermatol Venereol. 2016; 151(1): 55–76. MiyashiroD SanchesJA Paraneoplastic skin disorders: a review G Ital Dermatol Venereol 2016 151 1 55 76 Search in Google Scholar

[5] Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990; 323(25): 1729–35. DOI: 10.1056/NEJM199012203232503 AnhaltGJ KimSC StanleyJR KormanNJ JabsDA KoryM Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia N Engl J Med 1990 323 25 1729 35 10.1056/NEJM199012203232503 Open DOISearch in Google Scholar

[6] Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000; 43(4): 619–26. DOI: 10.1067/mjd.2000.107488 JolyP RichardC GilbertD CourvilleP ChosidowO RoujeauJC Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus J Am Acad Dermatol 2000 43 4 619 26 10.1067/mjd.2000.107488 Open DOISearch in Google Scholar

[7] Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. 2011; 29(3): 419–25, viii. DOI: 10.1016/j.det.2011.03.018 FrewJW MurrellDF Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis Dermatol Clin 2011 29 3 419 25 viii 10.1016/j.det.2011.03.018 Open DOISearch in Google Scholar

[8] Kim JH, Kim SC. Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa. Front Immunol. 2019; 10: 1259. DOI: 10.3389/fimmu.2019.01259 KimJH KimSC Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa Front Immunol 2019 10 1259 10.3389/fimmu.2019.01259 Open DOISearch in Google Scholar

[9] Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev. 2018; 17(10): 1002–1010. DOI: 10.1016/j.autrev.2018.04.008 AmberKT ValdebranM GrandoSA Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus Autoimmun Rev 2018 17 10 1002 1010 10.1016/j.autrev.2018.04.008 Open DOISearch in Google Scholar

[10] Nanda M, Nanda A, Al-Sabah H, Dvorak R, Alsaleh QA. Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int J Dermatol. 2007; 46(7): 767–9. DOI: 10.1111/j.1365-4632.2007.03225.x NandaM NandaA Al-SabahH DvorakR AlsalehQA Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone Int J Dermatol 2007 46 7 767 9 10.1111/j.1365-4632.2007.03225.x Open DOISearch in Google Scholar

[11] Izaki S, Yoshizawa Y, Kitamura K, Kato H, Hashimoto H, Korman NJ, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol. 1996; 134(5): 987–9. DOI: 10.1111/j.1365-2133.1996.tb06349.x IzakiS YoshizawaY KitamuraK KatoH HashimotoH KormanNJ Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis Br J Dermatol 1996 134 5 987 9 10.1111/j.1365-2133.1996.tb06349.x Open DOISearch in Google Scholar

[12] Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. Australas J Dermatol. 2017; 58(4): e240–e242. DOI: 10.1111/ajd.12615 LeeA SandhuS Imlay-GillespieL MulliganS ShumackS Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia Australas J Dermatol 2017 58 4 e240 e242 10.1111/ajd.12615 Open DOISearch in Google Scholar

[13] Ito Y, Makita S, Maeshima AM, Hatta S, Suzuki T, Yuda S, et al. Paraneoplastic pemphigus associated with b-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab. Intern Med. 2018; 57(16): 2395–2398. DOI: 10.2169/internalmedicine.0578-17 ItoY MakitaS MaeshimaAM HattaS SuzukiT YudaS Paraneoplastic pemphigus associated with b-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab Intern Med 2018 57 16 2395 2398 10.2169/internalmedicine.0578-17 Open DOISearch in Google Scholar

[14] Vezzoli P, Berti E, Marzano AV. Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Rev Clin Immunol. 2008; 4(3): 351–63. DOI: 10.1586/1744666X.4.3.351 VezzoliP BertiE MarzanoAV Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus Expert Rev Clin Immunol 2008 4 3 351 63 10.1586/1744666X.4.3.351 Open DOISearch in Google Scholar

[15] Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d’Amore F. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol. 2013; 169(2): 469–72. DOI: 10.1111/bjd.12324 BechR Baumgartner-NielsenJ PeterslundNA SteinicheT DeleuranM d’AmoreF Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus Br J Dermatol 2013 169 2 469 72 10.1111/bjd.12324 Open DOISearch in Google Scholar

[16] Gu L, Ye S. Tocilizumab cannot prevent the development of bronchiolitis obliterans in patients with castleman disease-associated paraneoplastic pemphigus. J Clin Rheumatol. 2019; 25(5): e77–e78. DOI: 10.1097/RHU.0000000000000675 GuL YeS Tocilizumab cannot prevent the development of bronchiolitis obliterans in patients with castleman disease-associated paraneoplastic pemphigus J Clin Rheumatol 2019 25 5 e77 e78 10.1097/RHU.0000000000000675 Open DOISearch in Google Scholar

[17] Lee J, Bloom R, Amber KT. A systematic review of patients with mucocutaneous and respiratory complications in paraneoplastic autoimmune multiorgan syndrome: Castleman's disease is the predominant malignancy. Lung. 2015; 193(4): 593–6. DOI: 10.1007/s00408-015-9732-8 LeeJ BloomR AmberKT A systematic review of patients with mucocutaneous and respiratory complications in paraneoplastic autoimmune multiorgan syndrome: Castleman's disease is the predominant malignancy Lung 2015 193 4 593 6 10.1007/s00408-015-9732-8 Open DOISearch in Google Scholar